

MINIREVIEW

Choline Transport for Phospholipid Synthesis

VERA MICHEL,* ZONGFEI YUAN,* SHOBHA RAMSUBIR,† AND MARICA BAKOVIC*,¹

**Department of Human Health and Nutritional Sciences, University of Guelph, Guelph, Ontario, Canada N1G 2W1; and †Ontario Cancer Institute, Division of Stem Cell and Differentiation, University Health Network, Toronto, Ontario, Canada M5G 2M1*

Choline is an essential nutrient for all cells because it plays a role in the synthesis of the membrane phospholipid components of the cell membranes, as a methyl-group donor in methionine metabolism as well as in the synthesis of the neurotransmitter acetylcholine. Choline deficiency affects the expression of genes involved in cell proliferation, differentiation, and apoptosis, and it has been associated with liver dysfunction and cancer. Abnormal choline transport and metabolism have been implicated in a number of neurodegenerative disorders such as Alzheimer's and Parkinson's disease. Therefore, the study of choline transport and the characteristics of choline transporters are of central importance to understanding the mechanisms that underlie membrane integrity and cell signaling in such disorders. Kinetic studies with radiolabeled choline and inhibitors distinguish three systems for choline transport: (i) low-affinity facilitated diffusion, (ii) high-affinity, Na⁺-dependent transport, and (iii) intermediate-affinity, Na⁺-independent transport. It is only recently, however, that the proteins having transport characteristics of at least one of these systems have been identified. They include (i) polyspecific organic cation transporters (OCTs) with low affinity for choline, (ii) high-affinity choline transporters (CHT1s), and (iii) intermediate-affinity choline transporter-like (CTL1) proteins. CHT1 and CTL1 but not OCT transporters are selectively inhibited with hemicholinium-3 and essentially display characteristics of specialized transporters for targeted choline metabolism. CHT1 is abundant in neurons and almost exclusively supplies choline for acetyl-

choline synthesis. The focus here is more on newly-discovered CTL1 choline transporters. They are expressed in different organisms and cell types, apparently not for the biosynthesis of acetylcholine but for the production of the most abundant metabolite of choline, the membrane lipid phosphatidylcholine. *Exp Biol Med* 231:490–504, 2006

Key words: choline; phospholipids; choline transport; CTL1

Importance of Choline

In 1998, choline was identified as an essential nutrient for humans by the National Academy of Sciences, United States (1). Choline is a quaternary amine (trimethyl- β -hydroxy-ethylammonium) (2) and its concentration in plasma has a physiological range of 10–50 μ M (3). Choline is predominantly utilized for the synthesis of essential lipid components of the cell membranes, phosphatidylcholine (PC) and sphingomyelin, and for the production of potent lipid mediators such as platelet-activating factor and lysophosphatidylcholine (4). Quantitatively, PC is the most important metabolite of choline and accounts for approximately one-half of the total membrane lipid content (5). Similarly to folate, choline is a source of labile methyl groups (6). In the liver and kidney mitochondria, choline is oxidized to betaine (trimethylglycine), which then enters the one-carbon cycle and serves as a methyl donor in the remethylation of homocysteine to methionine, to ultimately generate the methylation agent S-adenosylmethionine (SAM; Ref. 7). Finally, choline is best known for its key role in neurons as the precursor of the neurotransmitter acetylcholine (8, 9). Acetylcholine could also be synthesized and released from nonneuronal cells; however, its role outside of neurons is not clearly defined (10).

The adequate intake level for choline is 550 mg/day for

This work was kindly supported by an Operating Grant from the Natural Sciences and Engineering Research Council of Canada to M.B. and the Ontario Government Premier Research Excellence Award to M.B.

¹ To whom correspondence should be addressed at Animal Science and Nutrition Building, Rm. 346, University of Guelph, Guelph, Ontario, Canada N1G 2W1. E-mail: mbakovic@uoguelph.ca

1535-3702/06/2315-0490\$15.00

Copyright © 2006 by the Society for Experimental Biology and Medicine

men and 425 mg/day for women (11). Choline content varies considerably among common foods (12) and dietary choline supplementation could improve multiple body functions, including cognition (13), learning, and memory (14, 15). Therefore, choline is an essential dietary component for the normal functioning of organisms. Here, we focus on specific aspects of choline research in recent years, including choline deficiency and choline metabolic pathways and transport, with emphasis on the emerging new families of transporters necessary for the production of PC, a lipid essential for the structural integrity and functioning of cell membranes.

Choline Deficiency

Healthy individuals meet or exceed the adequate intake levels for choline (16); however, certain population groups are at risk for choline deficiency. These include pregnant and lactating women, infants, cirrhosis patients, and patients depending on parenteral nutrition (17). Dietary choline deficiency in animal models causes spontaneous carcinoma of the liver and generally increases sensitivity to carcinogens (18). It is the only type of nutritional deficiency known to have such deleterious effect (19). A gradual reduction in choline supplementation initially causes apoptosis in rat hepatocytes (20, 21); however, when cells adapt to a low choline intake, they become resistant, and a tumorigenic transformation is frequently observed (21). Apoptosis induced by choline deficiency is p53-independent and is linked to TGF β 1 signaling and generation of reactive oxygen species, which disrupt the membrane potential and eventually lead to mitochondrial dysfunction and cell death (21, 22). Adaptive responses to deleterious effects of choline deficiency include increased transcription of the proto-oncogenes *c-myc*, *c-Ha-ras* and *c-fos*, and increased levels of proinflammatory cytokines such as TNF- α (23). Furthermore, it has recently been shown that choline deficiency affects the expression of 1000 genes in neural precursor cells, with one-third of the genes involved in the cell proliferation, differentiation, methyl-group metabolism, and apoptosis (24), demonstrating the essentiality of choline for proper cell function.

Because it is predominantly utilized for membrane PC, choline has a significant impact on liver function and systemic lipid metabolism. In experimental animals as well as in humans (25–28), choline deficiency results in the formation of “nonalcoholic fatty liver,” associated with accumulation of hepatic lipids and an increased sensitivity to inflammation (29). In knockout mouse models lacking liver CTP:phosphocholine cytidyltransferase (Pcyt1), which is the major regulatory enzyme in PC synthesis, hepatic PC decreases and an accumulation of triglycerides in the liver is observed. At the same time, plasma lipids as well as plasma lipoprotein content become reduced (30). It is well established that homocysteine levels are elevated after a methionine load in choline-deficient individuals (26). The

interaction of choline with other nutrients in one-carbon metabolism and homocysteine production is becoming an increasingly important issue to be examined more actively in the future (31). The close relationship between choline and folate/methionine metabolism offers an opportunity for improved assessment of human susceptibility to choline status, development of nonalcoholic fatty liver, and development of cancer. The risk assessment based on genetic variations may offer novel preventive strategies for similar diseases. The relationship between folate deficiency and polymorphisms of the 5,10-methylenetetrahydrofolate reductase (MTHFR) gene is well-known; it resulted in widespread supplementation of food products with folate to prevent development of birth defects (32). Choline deficiency is not related to the variations in the MTHFR gene; however, the polymorphism of 5,10-methylenetetrahydrofolate dehydrogenase (MTHFDH) is a significant risk factor. When placed on a choline-deficient diet, carriers of the most common allele, MTHFDH1958A, become depleted of choline faster than noncarriers (27).

During pregnancy, fetal plasma choline levels are several-fold higher compared with choline levels in maternal plasma, which may result in a depletion of maternal choline stores (29), implicating the importance of choline for the developing fetus. In a normal pregnancy, plasma choline levels rise constantly throughout the gestation period (33), coinciding with elevated homocysteine levels (34), which indicates that the high fetal demand for choline may stimulate an increased choline synthesis in the maternal liver (34). Choline supplements during pregnancy have been shown to improve lifelong memory in rats (35). Adult offspring of mothers that had received choline supplements were more adept at tasks involving spatial and temporal memory and attention (35–37), and these behavioral effects persisted beyond the age of 2 years. These data suggest that choline has a permanent developmental effect on brain organization and function (1). Furthermore, consuming foods high in choline during pregnancy may reduce the risk of neural tube defects; this is attributed mainly to the role of choline as a methyl-group donor (38). More on choline deficiency and the relationship between choline, the one-carbon cycle, and lipid metabolism is discussed in the following sections on choline metabolic pathways and transport.

Choline Metabolic Pathways

The majority of cellular choline is phosphorylated by choline kinase (CK) to phosphocholine, to which CTP can then be added by Pcyt1 to yield CDP-choline. The formation of PC results from the reaction of CDP-choline with diacylglycerol (DAG), catalyzed by CDP-choline: DAG cholinephosphotransferase (CPT; Fig. 1). This pathway is known as the Kennedy (CDP-choline) pathway for *de novo* synthesis of PC and is essential for the formation of membrane PC in all nucleated cells. Since its discovery in




Figure 1. Choline metabolic pathways. ADP, adenosine diphosphate; ATP, adenosine triphosphate; BHMT, betaine:homocysteine methyltransferase; B12, vitamin B12; CDP, cytidine diphosphate; CK, choline kinase; CPT, CDP-choline:DAG cholinephosphotransferase; CMP, cytidine monophosphate; CTP, cytidine triphosphate; DAG, diacylglycerol; MAT, methionine adenosyltransferase; methylTHF, 5-methyl-tetrahydrofolate; MS, methionine synthase; MTHF, 5,10-methylene-tetrahydrofolate; PAF, platelet-activating factor; PCP, phosphatidylcholine:ceramidecholine phosphotransferase; Pcyt1, CTP:phosphocholine cytidyltransferase; PEMT, phosphatidylethanolamine *N*-methyltransferase; PLA, phospholipase A2; PPI, pyrophosphate; SAH, *S*-adenosylhomocysteine; SAM, *S*-adenosylmethionine; THF, tetrahydrofolate.

the 1950s by Eugene Kennedy, this pathway has been extensively studied, and most aspects of its regulation are well established. In recent years, focus is more on cloning and characterization of genes participating in the pathway (39–43), with emphasis on the rate-regulatory gene *Pcyt1* (44–46); the Kennedy pathway is not considered to be regulated by other steps in the pathway, nor by the rate of choline transport.

During evolution, the liver has retained a backup pathway for choline production from the second most abundant membrane phospholipids, phosphatidylethanolamine (PE; Fig. 1), to provide this essential metabolite when dietary choline is limited, as, for example, during starvation, embryonic development, pregnancy, or lactation. PE is transformed to PC in a three-step methylation by SAM, which is catalyzed by phosphatidylethanolamine-*N*-methyltransferase (PEMT). The PE methylation pathway has been extensively studied by Dr. Dennis Vance and his collaborators (for reviews see Refs. 47, 48). More recently, his laboratory developed a *PEMT* knockout mouse model, providing valuable data on the role of this pathway in the liver, PC synthesis, lipoprotein secretion, and bile and homocysteine production (42, 49).

Liver choline/phospholipid and methionine/homocysteine pathways are interrelated by their need for methyl groups provided by SAM (Fig. 1). When PE methylation is blocked, as it is in *PEMT* knockout mice (*PEMT*^{-/-}), plasma

homocysteine is 50% lower than in wild-type *PEMT*^{+/+} mice (50). On the other hand, mice having *Pcyt1 α* conditionally deleted in macrophages have elevated plasma homocysteine because of an increased methylation of PE, to compensate for the dysfunctional CDP-choline pathway (49). When fed a choline-deficient diet, the *PEMT*^{-/-} mouse dies because of hepatic depletion of PC. When fed a regular diet, the mouse is normal, because the *PEMT*^{-/-} liver can utilize dietary choline *via* the CDP-choline pathway. The *PEMT*^{-/-} animals develop an anomalous lipoprotein profile and a “fat-liver” phenotype when fed a high-fat/high-cholesterol, “Western-style” diet (51). Surprisingly, double-knockout *PEMT*^{-/-}/*MDR2*^{-/-} mice (*MDR2* is a hepatic P-glycoprotein that exports PC into bile) survive on a choline-deficient diet (52). In these animals, choline is recycled *via* increased PC metabolism and increased flux through the CDP-choline pathway, as well as by suppression of choline oxidation to betaine (Fig. 1). Therefore, it becomes apparent that *PEMT*^{-/-} mice die on a choline-deficient diet because these pathways do not compensate the PC drain into bile. Together, these invaluable studies strongly demonstrate the importance of proper metabolic balances between choline, SAM, PE, and PC in liver function, and make the pathways (shown in Fig. 1) for their regulation significant risk factors for development of “fatty-liver” steatosis, hyperlipoproteinemia, hyperhomocysteinemia, and cardiovascular disease.

Importance of Choline Transport

Separately from choline metabolism, disturbed choline transport has been proposed to play an important role in multiple clinical manifestations, particularly in neurological, muscular, and immunological disorders (53, 54) and in various cancers, including breast and ovarian cancer (55, 56). However, choline transport has been studied predominantly in neurodegenerative disorders, particularly in Alzheimer's disease. Alzheimer's disease is manifested with the specific loss of cholinergic neurons, and choline transport is an attractive target for drug development to treat the disease (57). It is now clear that choline is provided to cholinergic neurons by a high-affinity transport system, which controls the formation of acetylcholine (57) and as such is of the greatest interest in this disorder (58). In addition, a low-affinity choline transport system unrelated to cholinergic transport has often been irregular in the erythrocytes of Alzheimer's disease patients (59). A reduced choline level in the cerebrospinal fluid of Parkinson's disease and Huntington's disease patients is a result not only of impaired choline transport but also of a modified phospholipid output (60, 61). A lower phospholipid output could result in membrane damage, in addition to the disturbances in neurotransmitter production that are very common in neurological disorders. In Friedreich's ataxia, the PC molecules incorporated into the membrane of certain cells are abnormal in that they contain a low percentage of linoleic acid (62). Emerging new data (discussed below) suggest that choline carriers that participate in PC metabolism, not only in neuronal cells but in most cells, are distinct from cholinergic carriers. These cells typically have a medium to low affinity for choline and could be choline-specific, polyspecific for various organic cations, or both. Therefore, besides the independent regulation of intracellular choline utilization for PC production in the Kennedy pathway and in liver PE methylation, complex transport systems for choline to enter and/or exit specialized cells are required in order to adjust free choline with specific cellular demands for choline, which, when disturbed, could have serious implications for membrane fluidity and function in all tissues.

Systems for Choline Transport

Choline is a positively charged quaternary amine and requires a protein-mediated mechanism to effectively pass the membrane lipid barrier. The mechanisms underlying choline transport have not been completely elucidated; however, three protein-mediated and thus saturable uptake systems, following Michaelis-Menten kinetics, are well documented (63–68). The first mechanism is the facilitated diffusion that has an apparent K_m of 10 μM of choline, driven by a choline concentration gradient as described in red blood cells (64). The second is a high-affinity, Na^+ - and energy-dependent transport system with a K_m of 0.5–3 μM that is sensitive to inhibition by low concentration of

hemicholinium-3 (HC-3, K_i of 1–3 μM ; Ref. 65). This “active transport” system is coupled to the biosynthesis of acetylcholine and is primary to neuronal tissues (65). The third, also “active transport,” system, which is somewhat lower in affinity for choline ($K_m \approx 20$ –200 μM), is ubiquitously distributed, and less effectively inhibited by HC-3 ($K_i \approx 20$ –200 μM) than the neuronal system (66–68). This system operates in most cells as a means of choline uptake for the purpose of phospholipid synthesis.

Many organs, such as lung, brain, placenta, kidney, and liver have acquired one or a combination of several choline transport systems, which allow them to fulfill specific functions. The alveoli of the lungs are lined with pulmonary surfactant, which is a PC phospholipid-protein complex that promotes lung stability (69). The physiological activity of the surfactant is largely attributable to the unique PC component of the surfactant, disaturated phosphatidylcholine (69). In all other cells in the lung, the major source of PC is the Kennedy (CDP-choline) pathway, which requires the circulating choline to be transported into the lung by the alveolar epithelium. It has been suggested that this transcellular transport process may be rate-limiting for the biosynthesis of pulmonary PC (70, 71). In addition, alveolar type II epithelial cells have developed two types of “active” choline transport mechanisms to regulate the pulmonary choline content (68): The first is a high-affinity, Na^+ -dependent system (K_m of 1.5 μM ; K_i of 1.7 μM for HC-3) resembling the neuronal transport, and the second is a Na^+ -independent system that has a lower affinity for choline (K_m of 19 μM ; K_i of 12 μM for HC-3), resembling the choline-specific but nonneuronal transport. There is also a third, very slow residual transport, which is presumed to be by passive diffusion.

The central nervous system requires choline for the synthesis of membrane phospholipids and for acetylcholine. In the brain, choline that is transported *via* the “high-affinity” system is destined for acetylcholine synthesis, whereas the “lower-affinity” system supplies choline for phospholipid synthesis (72). The ranges of affinity for these systems could vary and depend on the region of the brain in which they are located, suggesting that a combination of choline carriers could be involved. Because the brain cannot synthesize *de novo* choline, choline uptake from extracellular fluids is essential (73). Choline enters the brain from the systemic circulation by a saturable transport at the blood-brain barrier (BBB) at a rate proportional to changes in the blood choline concentration, thus representing a facilitated diffusion process (72). Human keratinocytes express a Na^+ -independent, polyspecific choline transport system similar to the choline carrier in the BBB and intestinal epithelial cells. This choline carrier has relevance both for the biosynthesis of skin lipids and for the uptake of cationic drugs into the keratinocytes, as it does at the BBB (28).

The importance of placental choline has been demonstrated in studies in which mouse embryos showed growth

retardation and developmental defects of the neural tube and face during neurulation when either choline uptake or metabolism was inhibited (7). The placenta possesses a choline transport mechanism, which is essential because a growing fetus has to derive all its metabolic choline requirements from its mother *via* the placenta (74). It has both a passive diffusion system and an active carrier-mediated process of low affinity with a K_m of 350 μM choline (75). Passive diffusion is the least physiologically relevant type of choline transport, considering positively-charged choline molecules and the blood concentration of choline, which is in the 10–50 μM range. More relevant is the active choline transport, as present at the apical side of BeWo and JEG-3 epithelial cells of the human placenta (76). The uptake is Na^+ -independent and saturable, with a K_m of 108 μM and 206 μM , respectively. Several cationic drugs, including diphenhydramine, etilefrine, clonidine, ranitidine, and butylscopolamine interact with this transport system and could be instrumental in the drug's transferring from the maternal blood to the fetal circulation (76).

All ingested choline and free choline generated by phospholipid metabolism enters the hepatic circulation, making the liver, where, as discussed earlier, there are very active biochemical pathways for choline metabolism, a significant "sink" for choline (Fig. 1). The liver contains a transport system resembling the "low-affinity" facilitated diffusion, but multiple systems are also detectable under different conditions (77). Studies of rat liver plasma membrane vesicles have demonstrated the presence of a basolateral transport for both choline and organic cations (77). It seems that the murine transporter organic cation transporter (OCT) 1 is responsible for the most of the hepatic choline and cationic drug circulation (78). At present, it is unknown whether a choline-specific transport is operating in the liver or whether different systems could be present at different membrane sites.

Renal tubular transport of choline is of importance because it maintains the plasma choline concentration within relatively narrow limits by employing both net secretion and reabsorption (79). When choline is presented to the kidney in excess of a species-specific threshold concentration, it will be excreted from the kidney into the urine (80). If the plasma concentration is below this level, choline will be reabsorbed into the kidney, not excreted (80). Membrane transport of choline is elevated in renal failure in erythrocytes and cerebral tissue, but the origins and clinical importance of that are unknown. (53). OCT1, for example, is localized in the basolateral membrane of renal proximal tubules, in intestinal enterocytes, and in the sinusoidal membrane of hepatocytes, where it probably mediates the efflux of many organic cations, including choline. The substrate specificity of rat OCT1 is for more hydrophilic (type 1) cations like tetra-ethyl ammonium and choline. Quinine, quinidine, and cyanine 863, which have been classified as type 2 cations, are not eliminated with rat OCT1 (81). The secretion (efflux) of organic cations by

renal proximal tubule is electrogenic, facilitated diffusion, and it is associated with basolateral uptake of type 1 organic cations. These processes are also believed to support electroneutral organic cation/organic cation exchange. An extensive presentation of renal polyspecific transport of organic cations is described by Wright and Dantzler (82).

Choline Transporters

Different families of proteins that have either been demonstrated or thought to play a role in choline transport have been isolated in a variety of species. The most prominent are (i) the high-affinity choline transporter family (CHT), (ii) the family of OCTs, and (iii) the choline transporter-like family (CTL). They exhibit varying affinities not only for choline transport but also for transport of a number of other organic cations (Table 1). Studies of the effect of various organic cation inhibitors revealed that hemicholinium-3 is the most effective inhibitor of choline uptake. Although CHT transporters are mostly important for choline transport for acetylcholine synthesis rather than for lipid synthesis, we want to include a brief summary of these high-affinity transport systems to complete the picture of choline transport. Comprehensive reviews of CHT are presented by Ferguson and Blakely (83) and Sarter and Parikh (84).

High Affinity Choline-Specific Transporters

Cholinergic neurotransmission plays an important role in regulation of many physiological functions (85–88). It is well known that basal forebrain cholinergic neurons are involved in learning and memory processes, and that hypoactivity of the cholinergic system is responsible for the cognitive deficit in Alzheimer's disease (4). Na^+ -dependent and HC-3-sensitive choline transport is very active in presynaptic terminals, and it is mediated by a high-affinity choline transporter. After many years of searching, this transporter, named CHT1, has recently been successfully cloned, first from *Caenorhabditis elegans* (*cho-1*) and rat (*rCHT1*; Ref. 89), and subsequently from humans (*hCHT1*; Refs. 90, 91), *Limulus* (LchCoT; Ref. 92), and mouse (*mCHT1*; Ref. 93). Based on the cDNA sequence, there is a high degree of conservation among CHT1 proteins, and their closest structural similarity is with the Na^+ -dependent glucose transporter SGLT (89). *hCHT1* is located on chromosome 2q12. The entire gene is ≈ 25 kb long and contains 9 exons. *hCHT1* protein is made of 580 amino acids with a predicted molecular mass of 63 kDa and could form 13 transmembrane domains (90, 91, 94). CHT1 mRNA expression is restricted to the brain regions rich in cholinergic neurons, like the forebrain, striatum, brain stem, and spinal cord (89–93). Recently, however, CHT1 transcripts have been also detected in nonneuronal cells, but the function of CHT1 outside of neurons is not known (95–97).

Now it is clear that CHT1 provides choline for the synthesis of acetylcholine in all cholinergic neurons (92–

Table 1. Choline Transporters: Affinity, Localization, and Expression

	Name	Chromosome	Organism	Tissue distribution ^a	References
Choline-specific					
I. CHT1s	hCHT1 ^b	2q12	Human	Brain, spinal cord	90, 91
	mCHT1	17D	Mouse	Brain, spinal cord	93
	rCHT1 ^b	9q11	Rat	Brain, spinal cord	89
	CHO-1	IV	<i>C. elegans</i>	Brain synaptic vesicles	89
II. CTL1s	hCTL1 ^b	9q31.2	Human	Multiple tissues ^{ac}	149, 150
	mCTL1	4B2	Mouse	Muscle	151
	rCTL1	5q24	Rat	Brain, spinal cord, colon ^d	148, 149
	tCTL1		Torpedo	Central nervous system, myelin	149,152
Choline-nonspecific					
OCTs	hOCT1	6q26	Human	Liver,	120, 140
	hOCT2	6q26	Human	Kidney, brain	120, 140
	mOCT1	17A1	Mouse	Intestine, liver, kidney	121
	mOCT2	17A1	Mouse	Kidney	124
	rOCT1 ^b	1q11–q12	Rat	Liver, kidney, intestine ^d	119, 129, 130, 141
	rOCT2 ^b	1q11	Rat	Kidney ^d	122, 125, 130, 139

^a Detection by mRNA.

^b Antibody being developed.

^c Detection by Western blotting.

^d Detection by either RT-PCR, immunohistochemistry, or *in situ* hybridization.

94). Functional expression of rat CHT1 in *Xenopus* oocytes or COS-7 cells produces typical high-affinity choline uptake that is identical with the high-affinity choline uptake in synaptosomes: (i) K_m for choline of 2 μM , (ii) inhibition by CH-3 with K_i of 2–5 nM, and (iii) Na^+ and Cl^- ion dependence (94). Apart from these cholinergic transport characteristics, the regulation of CHT expression is becoming increasingly important. It has been shown that CHT1 could be regulated by neuronal depolarization (98–102), second messengers (103–105), and acute drug treatments (106–108). CHT1 contains serine and threonine residues for regulation of function and surface expression by protein kinase C (PKC; Refs. 92, 94) and protein phosphatase 1/2A (PP1/PP2A; Ref. 92). It seems a very common phenomenon that PKC and PP1/PP2A regulate neurotransmitter transporter proteins *via* rapid changes in transporter surface expression and phosphorylation (109). Recently it was reported that prostate apoptosis response-4 (Par-4), a leucine zipper protein that plays an important role in neuronal dysfunction and cell death in neurodegenerative disorders such as Alzheimer's disease (88, 110–116), inhibits CHT1-mediated choline uptake activity and reduces the cell surface expression of CHT1 by directly interacting with CHT1 (88). The importance of the biological function of CHT1 has been further confirmed by the fact that disruption of CHT1 in mice is lethal to the neonate (117).

Low-Affinity Polyspecific Organic Cation Transporters

The transport of endogenous organic cations, clinical drugs, and exogenous toxic cations is generally mediated by the family of OCTs also known as the solute carrier 22 family of proteins (118). This family is comprised of five

members, including OCT1, OCT2, OCT3 (119–126), OCTN1 (127), and OCTN2 (128), and has been subject to ongoing intensive research since the initial cloning of OCT1 from a rat kidney library in 1994 (119). OCT1 is expressed in the liver, kidney, and small intestine in rodents (119, 121, 129, 130); however, in humans, it is mainly expressed in the liver (120). OCT2 has substrate specificity similar to that of OCT1, but its expression is limited to the kidney and specific regions in the brain (122, 131). OCT3 is expressed most abundantly in the placenta and moderately in the intestine, heart, and brain (Table 1; Ref. 132).

The functional characterizations from different species strongly suggest that OCT1, OCT2, and OCT3 facilitate polyspecific cationic transport (119–121, 128, 131–133). Regarding their physiological role in choline transport, however, the data are less extensive and the information varies in different experiments. In transiently transfected human embryonic kidney (HEK) 293 cells, choline was transported exclusively by OCT1, but not by OCT2 (134). When expressed in *Xenopus* oocytes, both OCT1 and OCT2 could facilitate choline uptake with low affinity, that is, K_m of 346 μM for rOCT1, 441 μM for rOCT2, and 102 μM for hOCT2 (135). OCT-1 and OCT2-mediated choline uptake could be inhibited by cimetidine (136) and larger, more hydrophobic cations like the antiarrhythmics quinine and quinidine (81, 135, 137). Disprocynium 24 and decynium 22, the most potent inhibitors recognized so far, inhibit OCT2 with K_i values around 10 nM (134, 138), and corticosterone, another potent inhibitor, inhibits OCT2 with K_i values around 200 nM (137). Disprocynium 24, decynium 22, and corticosterone are less effective with OCT1 (134, 137). The major driving force for choline transport *via* OCT1 and OCT2 is the membrane potential




Figure 3. mCTL1 presents 10 transmembrane domains (TMDs) with a large and variable loop between TMDs 1 and 2, which is potentially glycosylated (N¹³⁴GSA¹³⁷). Potential protein kinase C phosphorylation sites were identified in the cytoplasmic domain (S¹²SK, T⁸⁶HR, T¹⁵¹SK, S²⁰⁹KE, S²⁶⁸PK, S⁵¹³AK, S⁶²⁸RK).

in human and rat (127, 128, 146, 147). However, choline is not a substrate of OCTN1 and OCTN2 (128, 147).

Choline-Specific Transporter-Like Proteins

The choline transporter-like proteins of the CTL family are comprised of the five genes, CTL1-CTL5, with CTL1 being the main member of the family (148). In 2000, O'Regan *et al.* (149) first cloned and characterized *Torpedo marmorata* CTL1 (*tCTL1*) and rat CTL1 (*rCTL1*). Subsequently the human form was cloned by Dr. Stockinger's laboratory (*hCTL1/CDw92*; Ref. 150), and we have cloned the mouse form, *mCTL1* (151). It is interesting that the *tCTL1* was isolated by complementation of a yeast strain defective in choline transport and that *hCTL1* was cloned from a cDNA expression library using a monoclonal antibody for the human antigen CDw92. CDw92 has a role in immune cell function as part of an auto-regulatory signaling loop that controls expression and maintenance of IL-10 production in dendritic cells (150). The function assigned to CDw92 as a choline transporter has been based on the cDNA sequence similarity to *rCTL1* and other family orthologs.

Mouse CTL2 and CTL4 cDNA have been initially identified in the Genbank libraries as members of this family (149); however, the mouse form of CTL1 was not detected, suggesting that this form could be rare or not present in the mouse. We searched for this rare form and were able to successfully clone the *mCTL1* cDNA from the mouse embryonic fibroblasts, to fully characterize the mouse gene that is localized at chromosome 4B2. Thus, we added a new member to the CTL1 family of proteins that is a choline transporter abundantly expressed in the mouse skeletal muscle, the function of which would be in transporting choline for phospholipid synthesis and/or choline recycling





Figure 4. (Top) Western blot of a mouse tissue protein panel showing that mCTL1 is expressed only in the skeletal muscle (Mu), but not in brain (Br), heart (He), small intestine (In), kidney (Ki), liver (Li), lung (Lu), ovary (Ov), stomach (St), spleen (Sp), and testis (Te). (Bottom) Western blot of a human tissue protein panel showing *hCTL1* expression as a major 50 kDa and a minor 23 kDa band in multiple tissues, including brain (BR), heart (He), small intestine (In), kidney (Ki), liver (Li), lung (Lu), skeletal muscle (Mu), pancreas (Pa), spleen (Sp), ovary (OV), and testis (Te).

at the neuromuscular junctions. The protein sequence alignment of mouse, rat, and human CTL1 is shown in Figure 2. They are all transmembrane proteins containing 10 highly conserved TMDs, possibly with intracellular N- and C-termini. Figure 3 shows that *mCTL1* protein contains three potential N-glycosylation sites (N¹³⁴GSA¹³⁷, N¹⁷⁹ISC¹⁸², N⁵⁰⁶STN⁵⁰⁹) and seven protein kinase C phosphorylation sites (S¹²SK, T⁸⁶HR, T¹⁵¹SK, S²⁰⁹KE, S²⁶⁸PK, S⁵¹³AK, S⁶²⁸RK), five of which are distributed within the N-terminal domain. Additionally (not shown), there is one cysteine-rich region (C⁴⁷³ARC⁴⁷⁶MLKS-C⁴⁸¹IC⁴⁸³C⁴⁸⁴LWC⁴⁸⁷LEKC⁴⁹¹) and one cadmium-resistance transporter domain between L²²⁰ and F³⁴¹, covering the membrane domains 3, 4, and 5.

The *hCTL1* gene is located at chromosome 9q31.2, the *rCTL1* gene at chromosome 5q24, and the *mCTL1* gene at chromosome 4B2. (Table 1). *tCTL1* mRNA is present throughout the central nervous system and along the electric nerves (152); *mCTL1* RNA is expressed in testis, brain, heart, and skeletal muscle, but the *mCTL1* protein is abundantly present only in the skeletal muscle (Fig. 4; Ref. 151). *hCTL1* protein is expressed as two major polypeptides of 50 and 23 kDa in a variety of tissues, including brain, heart, small intestine, kidney, liver, lung, skeletal muscle, pancreas, spleen, ovary, and testis (Fig. 4; Ref. 153). Rat *rCTL1a* mRNA is expressed in the ileum and colon, whereas *rCTL1b* mRNA is expressed exclusively in the brain (148, 149). Both isoforms of *rCTL1* were recently functionally expressed and identified as an intermediate-affinity, Na⁺-independent choline transport system in N18 neuroblastoma cells (148) and in astrocytes (154).

Two different splice variants have been identified in rat

A. hCTL1 Gene



B. C-Terminal Variants




Figure 5. Organization of the hCTL1 gene and its 3' end splicing. (A) The ≈ 194 -kb hCTL1 gene is made of 17 exons and 16 introns. The hCTL1a transcript is encoded by exons 1–16 and the hCTL1b transcript by exons 1–15 and exon 17. The 5'-flanking (regulatory promoter) region is 0.8 kb. The first two exons are separated by the large (54 kb) intron I. The alternatively expressed exons 16 and 17 at the 3' end are also divided by the large (47 kb) intron XVI. (B) Structure of the C-terminal peptides of the hCTL1a and hCTL1b proteins, showing that they are encoded by different exons.

(rCTL1a and rCTL1b) and humans (hCTL1a and hCTL1b; Refs. 148, 149, 153). The hCTL1 gene spans over 194 kb at chromosome 9q31.2 and consists of 17 exons and 16 introns (Fig. 5). The last two exons, 16 and 17, are alternatively spliced in the two isoforms hCTL1a and hCTL1b; hCTL1a is made of exons 1–16, whereas hCTL1b uses exons 1–15 and exon 17, resulting in distinct 3' UTRs in both isoforms (153). The alternative splicing produces proteins with differing C-terminal peptides, A⁶⁵¹SGASSA⁶⁵⁷ peptide in hCTL1a and L⁶⁵¹KKR⁶⁵⁴ peptide in CTL1b. Noteworthy, KKXX is a short carboxy-terminal signal that plays a crucial role for the localization in the endoplasmic reticulum. The existence of KKXX motif for hCTL1b would support the identification of the additional site for choline transport at the endoplasmic reticulum (148, 153, 155). Our human tissue expression profiles indicate that the hCTL1a mRNA is highly expressed in placenta and brain and the hCTL1b mRNA is most abundant in the liver (153). The significance of both hCTL1 isoforms has yet to be discovered.

The function of CTL1 as a choline transporter has recently been disputed. CTL1 was initially identified to restore choline transport in a triple yeast mutant strain (*ctr*

ise URA3Δ), which is deficient in both choline transport and neosynthesis under selective conditions (149, 156). Furthermore, expression of tCTL1 in *Xenopus* oocytes increased sodium-independent high-affinity choline uptake (156). However, Zufferey *et al.* reported that the loss of PNS1, a CTL1 homolog in yeast, does not impair choline transport, and that overexpression of both PNS1 and tCTL1 in transport-deficient mutants did not restore choline uptake in the yeast strain (157).

In our laboratory, we demonstrated a 2.5-fold increase in choline transport by overexpression of mCTL1 in Cos-7 cells (151). We also identified hCTL1 to be the predominant choline transporter in THP-1 cells and demonstrated that choline uptake is high in monocytic cells and severely reduced after PMA treatments as a result of diminished hCTL1 protein trafficking to the plasma membrane (Fig. 6). Our choline transport studies using [³H]-choline revealed that choline uptake in THP-1 cells was almost completely inhibited by HC-3, whereas OCT-specific inhibitors had no effect on choline transport. The transport was of intermediate affinity for choline ($K_m = 68 \pm 12 \mu M$), PMA-dependent and CTL1-related, because we strongly excluded




Figure 6. CTL1 disappearance from the membrane of THP-1 cells after treatment with 160 nM phorbol myristate 13-acetate (PMA). CTL1 was detected with a monoclonal anti-CDw92 antibody and a secondary AlexaFluor 568 antibody (Molecular Probes, Burlington, Canada). (A–C) Differential interference contrast (DIC) microscopy in (A) untreated cells, (B) 24-hr PMA treated cells, and (C) 48-hr PMA treated cells. (D–F) Confocal laser scanning microscopy of the same cells in (D) untreated cells, (E) 24-hr PMA treated cells, and (F) 48-hr PMA treated cells.

OCT and CHT1 as possible transporters (for recently published data, see ref. 158).

Three recent studies have given further strong support to the idea that CTL1 is in fact a choline transporter, as suggested by O'Regan's studies on rCTL1 and our studies on mCTL1. Inazu *et al.* (154) identified a Na^+ -independent, saturable choline transport system in rat astrocytes with an intermediate affinity for choline ($K_m = 37.7 \mu\text{M}$), which was likely CTL1. Interestingly, they reported an impaired choline transport with a decrease in pH, which may give an indication of a possible proton dependency of CTL1-mediated choline transport. Fujita *et al.* (159) report a Na^+ -dependent, saturable choline transport in mouse neurons of the cerebral cortex with an affinity for choline of $K_m = 26.7 \mu\text{M}$. The only member of the OCT group expressed in these cells is OCT3, which does not have choline as a substrate. Although CHT1, which is expressed by these mouse neurons, likely accounted for the Na^+ -dependent choline transport, CTL1 is most likely responsible for the Na^+ -independent choline transport observed in this study. Both of these recent studies imply that CTL1 could also play an

important role in the choline transport of neuronal cells. Choline transport by CTL1 has also recently been associated with amyloid- β -peptide (160), a fragment of amyloid precursor protein that shows an altered metabolism in Alzheimer's disease. A long-term treatment of NG108–15 cells with amyloid- β -peptide resulted in a downregulation of choline uptake by CTL1. Although CTL1 mRNA levels did not change and the amyloid- β -peptide therefore did not affect gene expression, the reduced choline uptake may be caused by changes in mechanisms downstream of gene expression. Importantly, similarly to our studies with THP-1 monocyte-macrophages cells (158), protein kinase C could be involved in the regulation of CTL1, because inhibition of PKC increases choline uptake, whereas after PKC activation choline uptake is impaired. Recently, both CTL1 and CHT mRNA expression has been shown to be upregulated by leukemia inhibitor factor, which further supports a regulation of CTL1 expression by PKC (161). Therefore, these data suggest that CTL1 may be involved in the pathogenesis of Alzheimer's disease, which further underlines its importance in the human metabolism.

Interestingly, we also demonstrated that hCTL1 protein is overexpressed in the skeletal muscle of muscular dystrophy patients (153). The CTL1 promoter contains a binding site for the MyoD transcription factor, which typically regulates muscle myogenesis by maintaining fast muscle fiber phenotypes as well as other regulatory functions (162). The remarkable regenerative capacity of skeletal muscle depends largely on the number of available satellite cells and their proliferative capacity (163). An increased macrophage accumulation can also be observed in the diseased or injured muscle, with the extent of macrophage accumulation correlating with protein clearance following injury and the efficiency of regeneration (164). The increase of hCTL1 protein in muscular dystrophy is a sign that the hCTL1 gene is responsive to processes common to degenerated muscle, and it could represent a target for improving muscle function.

Conclusions and Prospects

With the identification of three kinds of choline transport systems—facilitated diffusion (64), low-affinity (68), and high-affinity (65)—and the identification of three families of choline transport proteins—CHT, OCT, and CTL—it is now possible to further elucidate the role of choline transport in health and disease, and to identify possible practical applications in the treatment of disorders associated with abnormal choline metabolism. It is crucial to further investigate the regulation of choline transporters at the protein and RNA level and to clarify the role that protein kinase C may play, considering the fact that all choline transporters contain highly conserved potential PKC phosphorylation sites. The identification of choline binding sites and the precise mechanism of choline uptake of the different transporters, as well as the crystallization and identification of their tertiary structures, will present a further challenge in the future.

We apologize for the failure to cite many of the important and relevant papers in this field because of space limitations. We gratefully acknowledge the research and discussions contributed by members of our laboratory.

- Blusztajn JK. Developmental neuroscience: enhanced choline, a vital amine. *Science* 281:794–795, 1998.
- Sheard NF, Zeisel SH. Choline: an essential dietary nutrient? *Nutrition* 5:1–5, 1989.
- Sweet DH, Miller DS, Pritchard JB. Ventricular choline transport—a role for organic cation transporter 2 expressed in choroids plexus. *J Biol Chem* 276:41611–41619, 2001.
- Zeisel SH, da Costa KA, Franklin PD, Alexander EA, Lamont JT, Sheard NF, Beiser A. Choline: an essential nutrient for humans. *FASEB J* 5:2093–2098, 1991.
- Zeisel SH. Choline: essential for brain development and function. *Adv Pediatr* 44:263–295, 1997.
- Zeisel SH, Blusztajn JK. Choline and human nutrition. *Annu Rev Nutr* 14:269–296, 1994.
- Fisher MC, Zeisel SH, Mar MH, Sadler TW. Inhibitors of choline uptake and metabolism cause developmental abnormalities in neuroulating mouse embryos. *Teratology* 64:114–122, 2001.
- Blusztajn JK, Wurtman RJ. Choline and cholinergic neurons. *Science* 221:614–620, 1983.
- Wessler I, Kilbinger H, Bittenger F, Kirkpatrick CJ. The biological role of non-neuronal acetylcholine in plants and humans. *J Pharmacol* 85:2–10, 2001.
- Wessler I, Kirkpatrick CJ, Racké K. Non-neuronal acetylcholine, a locally acting molecule, widely distributed in biological systems: expression and function in humans. *Pharmacol Ther* 77:59–79, 1998.
- Institute of Medicine and National Academy of Sciences of the USA. Dietary Reference Intakes for Folate, Thiamin, Riboflavin, Niacin, Vitamin B12, Panthothenic Acid, Biotin, and Choline. Washington, DC: National Academic Press, Vol. 1:390–422, 1998.
- Zeisel SH, Mar MH, Howe JC, Holden JM. Concentrations of choline-containing compounds and betaine in common foods. *J Nutr* 133:1302–1307, 2003.
- Yang Y, Liu Z, Cermak JM, Tandon P, Sarkisian MR, Stafstrom CE, Neill JC, Blusztajn JK, Holmes GL. Protective effects of prenatal choline supplementation on seizure-induced memory impairment. *J Neurosci* 20:1–6, 2000.
- Garner SC, Mar MH, Zeisel SH. Choline distribution and metabolism in pregnant rats and fetuses are influenced by the choline content of the maternal diet. *J Nutr* 125:2851–2858, 1995.
- Cermak JM, Blusztajn JK, Meck WH, Williams CL, Fitzgerald CM, Rosene DL, Loy R. Prenatal availability of choline alters the development of acetylcholinesterase in the rat hippocampus. *Dev Neurosci* 21:94–104, 1999.
- Fischer LM, Scearce JA, Mar MH, Patel JR, Blanchard RT, Macintosh BA, Busby MG, Zeisel SH. Ad libitum choline intake in healthy individuals meets or exceeds the proposed adequate intake level. *J Nutr* 135:826–829, 2005.
- Zeisel SH. Choline, homocysteine and pregnancy. *Am J Clin Nutr* 82:719–720, 2005.
- Zeisel SH. Choline: an essential nutrient for humans. *Nutrition* 16:669–671, 2000.
- Zeisel SH. Choline: a nutrient that is involved in the regulation of cell proliferation, cell death, and cell transformation. In: Heber D, Kritchevsky D, eds. *Dietary Fats, Lipids, Hormones and Tumorigenesis*. New York: Plenum Press, pp131–141, 1996.
- Albright CD, Liu R, Bethea TC, Da Costa KA, Salganik RI, Zeisel SH. Choline deficiency induces apoptosis in SV-40 immortalized CWSV-1 rat hepatocytes in culture. *FASEB J* 10:510–516, 1996.
- Zeisel SH, Albright CD, Shin OH, Mar MH, Salganik RI, da Costa KA. Choline deficiency selects for resistance to p53-independent apoptosis and causes tumorigenic transformation of rat hepatocytes. *Carcinogenesis* 18:731–738, 1997.
- Guo WX, Pye QN, Williamson KS, Stewart CA, Hensley KL, Kotake Y, Floyd RA, Broyles RH. Mitochondrial dysfunction in choline deficiency-induced apoptosis in cultured rat hepatocytes. *Free Radic Biol Med* 39:641–650, 2005.
- Holmes-McNary MQ, Baldwin AS Jr., Zeisel SH. Opposing regulation of choline deficiency-induced apoptosis by p53 and nuclear factor κ B. *J Biol Chem* 276:41197–41204, 2001.
- Niculescu MD, Craciunescu CN, Zeisel SH. Gene expression profiling of choline-deprived neural precursor cells isolated from mouse brain. *Brain Res Mol Brain Res* 134:309–322, 2005.
- Kashireddy PR, Rao MS. Sex differences in choline-deficient diet-induced steatohepatitis in mice. *Exp Biol Med* (Maywood) 229:158–162, 2004.
- Da Costa KA, Gaffney CE, Fischer LM, Zeisel SH. Choline deficiency in mice and humans is associated with increased plasma homocysteine concentration after a methionine load. *Am J Clin Nutr* 81:440–444, 2005.
- Kohlmeier M, da Costa KA, Fischer LM, Zeisel SH. Genetic variation

- of folate-mediated one-carbon transfer pathway predicts susceptibility to choline deficiency in humans. *Proc Natl Acad Sci U S A* 102:16025–16030, 2005.
28. Hoffmann K, Grafe F, Wohlrab W, Neubert RH, Brandsch M. Functional characterization of a high-affinity choline transport system in human keratinocytes. *J Invest Dermatol* 119:118–121, 2002.
 29. Zeisel SH. Choline: an important nutrient in brain development, liver function and carcinogenesis. *J Am Coll Nutr* 11:473–481, 1992.
 30. Jacobs RL, Devlin C, Tabas I, Vance DE. Targeted deletion of hepatic CTP:phosphocholine cytidyltransferase alpha in mice decreases plasma high density and very low density lipoproteins. *J Biol Chem* 279:47402–47410, 2004.
 31. Davis CD, Uthus EO. DNA methylation, cancer susceptibility, and nutrient interactions. *Exp Biol Med (Maywood)* 229:988–995, 2004.
 32. Ray JG, Laskin CA. Folic acid and homocysteine metabolic defects and the risk of placental abruption, pre-eclampsia and spontaneous pregnancy loss: a systematic review. *Placenta* 20:519–529, 1999.
 33. Velzing-Aarts FV, Holm PI, Fokkema MR, van der Dijs FP, Ueland PM, Muskiet FA. Plasma choline and betaine and their relation to plasma homocysteine in normal pregnancy. *Am J Clin Nutr* 81:1383–1389, 2005.
 34. Molloy AM, Mills JL, Cox C, Daly SF, Conley M, Brody LC, Kirke PN, Scott JM, Ueland PM. Choline and homocysteine interrelations in umbilical cord and maternal plasma at delivery. *Am J Clin Nutr* 82:836–842, 2005.
 35. Meck WH, Williams CL. Simultaneous temporal processing is sensitive to prenatal choline availability in mature and aged rats. *Neuroreport* 8:3045–3051, 1997.
 36. Meck WH, Williams CL. Characterization of the facilitative effects of perinatal choline supplementation on timing and temporal memory. *Neuroreport* 8:2831–2835, 1997.
 37. Meck WH, Smith RA, Williams CL. Organizational changes in cholinergic activity and enhanced visuospatial memory as a function of choline administered prenatally or postnatally or both. *Behav Neurosci* 103:1234–1241, 1989.
 38. Shaw GM, Carmichael SL, Yang W, Selvin S, Schaffer DM. Periconceptional dietary intake of choline and betaine and neural tube defects in offspring. *Am J Epidemiol* 160:102–109, 2004.
 39. Kent C. Regulatory enzymes of phosphatidylcholine biosynthesis: a personal perspective. *Biochim Biophys Acta* 1733:53–66, 2005.
 40. Aoyama C, Liao H, Ishidate K. Structure and function of choline kinase isoforms in mammalian cells. *Prog Lipid Res* 43:266–281, 2004.
 41. McMaster CR, Bell RM. CDP-choline:1,2-diacylglycerolcholinephospho-transferase. *Biochim Biophys Acta* 1348:100–110, 1997.
 42. Vance JE, Vance DE. Metabolic insights into phospholipids function using gene-targeted mice. *J Biol Chem* 280:10877–10880, 2005.
 43. Jackowski S, Fagone P. CTP:phosphocholine cytidyltransferase: paving the way from gene to membrane. *J Biol Chem* 280:853–856, 2005.
 44. Bakovic M, Waite K, Tang W, Tabas I, Vance DE. Transcriptional activation of the murine CTP:phosphocholine cytidyltransferase gene (*Ctptc*): combined action of upstream stimulatory and inhibitory cis-acting elements. *Biochim Biophys Acta* 1438:147–165, 1999.
 45. Golfman LS, Bakovic M, Vance DE. Transcription of the CTP:phosphocholine cytidyltransferase alpha gene is enhanced during the S phase of the cell cycle. *J Biol Chem* 276:43688–43692, 2001.
 46. Bakovic M, Waite K, Vance DE. Oncogenic Ha-Ras transformation modulates the transcription of the CTP:phosphocholine cytidyltransferase alpha gene via p42/44MAPK and transcription factor Sp3. *J Biol Chem* 278:14753–14761, 2003.
 47. Vance DE. Phosphatidylethanolamine N-methyltransferase: unexpected findings from curiosity-driven research. *Eur J Med Res* 1:182–188, 1996.
 48. Vance DE, Walkey CJ, Cui Z. Phosphatidylethanolamine N-methyltransferase from liver. *Biochim Biophys Acta* 1348:142–150, 1997.
 49. Jacobs RL, Stead LM, Devlin C, Tabas I, Brosnan ME, Brosnan JT, Vance DE. Physiological regulation of phospholipid methylation alters plasma homocysteine in mice. *J Biol Chem* 280:28299–28305, 2005.
 50. Noga AA, Stead LM, Zhao Y, Brosnan ME, Brosnan JT, Vance DE. Plasma homocysteine is regulated by phospholipid methylation. *J Biol Chem* 278, 5952–5955, 2003.
 51. Noga AA, Vance DE. A gender-specific role for phosphatidylethanolamine N-methyltransferase-derived phosphatidylcholine in the regulation of plasma high density and very low density lipoproteins in mice. *J Biol Chem* 278:21851–21859, 2003.
 52. Li Z, Agellon LB, Vance DE. Phosphatidylcholine homeostasis and liver failure. *J Biol Chem* 280:37798–37802, 2005.
 53. Riley SP, Talbot NJ, Ahmed MJ, Jouhal K, Hendry BM. Characterization of human erythrocyte choline transport in chronic renal failure. *Nephrol Dial Transplant* 12:1921–1927, 1997.
 54. Hendry BM. Membrane transport in uraemia. In: Raine AEG, Ed. *Advanced Renal Medicine*. New York: Oxford University Press, pp16–24, 1992.
 55. Iorio E, Mezzanzanica D, Alberti P, Spadaro F, Ramoni C, D'Ascenzo S, Millimaggi D, Pavan A, Dolo V, Canevari S, Podo F. Alterations of choline phospholipid metabolism in ovarian tumor progression. *Cancer Res* 65:9369–9376, 2005.
 56. Villa A, Caporizzo E, Papagni A, Miozzo L, Buttero P, Grilli M, Amboldi N, Fazio F, Doglia S, Giglioni B. Choline and phosphatidylcholine fluorescent derivatives localization in carcinoma cells studied by laser scanning confocal fluorescence microscopy. *Eur J Cancer* 41:1453–1459, 2005.
 57. Wecker L. Dietary choline. A limiting factor for the synthesis of acetylcholine by the brain. *Adv Neurol* 51:139–145, 1990.
 58. Slotkin TA, Nemeroff CB, Bissette G, Seidler FJ. Overexpression of the high affinity choline transporter in cortical regions affected by Alzheimer's disease. Evidence from rapid autopsy studies. *J Clin Invest* 94:696–702, 1994.
 59. Miller BL, Jenden DJ, Cummings JL, Read S, Rice K, Benson DF. Abnormal erythrocyte choline and influx in Alzheimer's disease. *Life Sci* 10:485–490, 1986.
 60. Manyam BV, Giacobini E, Colliver JA. Cerebrospinal fluid choline levels are decreased in Parkinson's disease. *Ann Neurol* 27:683–685, 1993.
 61. Manyam BV, Giacobini E, Colliver JA. Cerebrospinal fluid acetylcholine-esterase and choline measurements in Huntington's disease. *J Neuro* 237:281–284, 1990.
 62. Barbeau A. Friedreich's ataxia 1979: an overview. *Can J Neurol Sci* 6:311–319, 1979.
 63. Fisher AB, Dodia C, Chander A, Kleinzeller A. Transport of choline by plasma membrane vesicles from lung-derived epithelial cells. *Am J Physiol* 263:C1250–C1257, 1992.
 64. Deves R, Krupker RM. The binding and translocation steps in transport as related to substrate structure. A study of choline carrier of erythrocytes. *Biochim Biophys Acta* 557:468–485, 1979.
 65. Simon JR, Atweh S, Kuhar MJ. Sodium-dependent, high affinity choline uptake: a regulatory step in the synthesis of acetylcholine. *J Neurochem* 26:909–922, 1976.
 66. Grassl SM. Choline transport in human placental brush-border membrane vesicles. *Biochim Biophys Acta* 1194:203–213, 1994.
 67. Porter RK, Scott JM, Brand MD. Choline transport into rat liver mitochondria. Characterization and kinetics of a specific transporter. *J Biol Chem* 267:14637–14646, 1992.
 68. Van Rossum GDV, Boyd CAR. Sodium-dependent and -independent choline uptake by type II epithelial cells from rat lung. *J Membr Biol* 162:147–156, 1998.

69. Van Golde LMG. Metabolism of phospholipids in the lung. *Am Rev Respir Dis* 114:977–1000, 1976.
70. Johnson RG, Lugg MA, Nicholas TE. Uptake of [¹⁴C]-choline and incorporation into lung phospholipids by the isolated rat lung. *Lipids* 14:555–558, 1978.
71. Yost RW, Chander A, Dodia C, Fisher AB. Synthesis of phosphatidylcholine by rat lung during choline deficiency. *J Appl Physiol* 61:2040–2044, 1986.
72. Klein J, Koppen A, Loffelholz K, Schmitthener J. Uptake and metabolism of choline by rat brain after acute choline administration. *J Neurochem* 58:870–876, 1992.
73. Wurtman RJ. Choline metabolism as a basis for the selective vulnerability of cholinergic neurons. *Trends Neurosci* 15:117–122, 1992.
74. Zeisel SH, Mar MH, Zhou Z, da Costa KA. Pregnancy and lactation are associated with diminished concentrations of choline and its metabolites in rat liver. *J Nutr* 125:3049–3054, 1995.
75. Welsch F. Choline metabolism in human term placenta. *Biochem Pharmacol* 27:1251–1257, 1978.
76. Müller J, Born I, Neubert RH, Brandsch M. Apical uptake of choline and cationic drugs in epithelial cell lines derived from human placenta. *Placenta* 26:183–189, 2005.
77. Kwon Y, Lee RD, Morris ME. Hepatic uptake of choline in rat liver basolateral and canalicular membrane vesicle preparations. *J Pharmacol Exp Ther* 279:774–778, 1996.
78. Sinclair CJ, Chi KD, Subramanian V, Ward KL, Green RM. Functional expression of a high affinity mammalian hepatic choline/organic cation transporter *J Lipid Res* 41:1841–1848, 2000.
79. Dantzer WH, Evans KK, Wright SH. Basolateral choline transport in isolated rabbit renal proximal tubules. *Pflügers Arch* 436:899–905, 1998.
80. Acara M. The kidney in the regulation of plasma choline in the chicken. *Am J Physiol* 228:645–649, 1975.
81. Nagel G, Volk C, Friedrich T, Ulzheimer JC, Bamberg E, Koepsell H. A reevaluation of substrate specificity of the rat cation transporter rOCT1. *J Biol Chem* 272:31953–31956, 1997.
82. Wright SH, Dantzer WH. Molecular and cellular physiology of renal organic cation and anion transport. *Physiol Rev* 84:987–1049, 2004.
83. Ferguson SM, Blakely RD. The choline transporter resurfaces: new roles for synaptic vesicles? *Mol Interv* 4:22–37, 2004.
84. Sarter M, Parikh V. Choline transporters, cholinergic transmission and cognition. *Nat Rev Neurosci* 6:48–56, 2005.
85. Winkler J, Suhr ST, Gage FH, Thal LJ, Fisher LJ. Essential role of neocortical acetylcholine in spatial memory. *Nature* 375:484–487, 1995.
86. Dickinson-Anson H, Winkler J, Fisher LJ, Song HJ, Pu M, Gage FH. Acetylcholine-secreting cells improve age-induced memory deficits. *Mol Ther* 8:51–61, 2003.
87. Warburton EC, Koder T, Cho K, Massey PV, Duguid G, Barker GRI, Aggleton JP, Bashir ZI, Brown MW. Cholinergic neurotransmission is essential for perirhinal cortical plasticity and recognition memory. *Neuron* 38:987–996, 2003.
88. Xie J, Guo Q. Par-4 inhibits choline uptake by interacting with CHT1 and reducing its incorporation to the plasma membrane. *J Biol Chem* 279:28266–28275, 2004.
89. Okuda T, Haga T, Kanai Y, Endou H, Ishihara T, Katsura I. Identification and characterization of the high affinity choline transporter. *Nat Neurosci* 3:120–125, 2000.
90. Apparsundaram S, Ferguson SM, George AL Jr, Blakely RD. Molecular cloning of a human, hemicholinium-3-sensitive choline transporter. *Biochem Biophys Res Commun* 276:862–867, 2000.
91. Okuda T, Haga T. Functional characterization of the human high-affinity choline transporter. *FEBS Lett* 484:92–97, 2000.
92. Wang Y, Cao Z, Newkirk RF, Ivy MT, Townsel JG. Molecular cloning of a cDNA for a putative choline co-transporter from *Limulus* CNS. *Gene* 268:123–131, 2001.
93. Apparsundaram S, Ferguson SM, Blakely RD. Molecular cloning and characterization of a murine hemicholinium-3-sensitive choline transporter. *Biochem Soc Trans* 29:711–716, 2001.
94. Okuda T, Haga T. High-affinity choline transporter. *Neurochem Res* 28:483–488, 2003.
95. Pfeil U, Haberberger RV, Lips KS, Eberling L, Grau V, Kummer W. Expression of the high-affinity choline transporter CHT1 in epithelia. *Life Sci* 72:2087–2090, 2003.
96. Pfeil U, Lips KS, Eberling L, Grau V, Haberberger RV, Kummer W. Expression of the high-affinity choline transporter, CHT1, in the rat trachea. *Am J Respir Cell Mol Biol* 28:473–477, 2003.
97. Haberberger RV, Pfeil U, Lips KS, Kummer W. Expression of the high-affinity choline transporter, CHT1, in the neuronal and non-neuronal cholinergic system of human and rat skin. *J Invest Dermatol* 119:943–948, 2002.
98. Barker LA. Modulation of synaptosomal high affinity choline transport. *Life Sci* 18:725–731, 1976.
99. Murrin LC, Kuhar MJ. Activation of high-affinity choline uptake in vitro by depolarizing agents. *Mol Pharmacol* 12:1082–1090, 1976.
100. Roskoski R Jr. Acceleration of choline uptake after depolarization-induced acetylcholine release in rat cortical synaptosomes. *J Neurochem* 30:1357–1361, 1978.
101. Sherman KA, Zigmond MJ, Hanin I. High affinity choline uptake in striatum and hippocampus: differential effects of treatments which release acetylcholine. *Life Sci* 23:1863–1870, 1978.
102. O'Regan S, Collier B. Factors affecting choline transport by the cat superior cervical ganglion during and following stimulation, and the relationship between choline uptake and acetylcholine synthesis. *Neuroscience* 6:511–520, 1981.
103. Cancela JM, Bertrand N, Beley A. Involvement of cAMP in the regulation of high affinity choline uptake by rat brain synaptosomes. *Biochem Biophys Res Commun* 213:944–949, 1995.
104. Volgelsberg V, Neff NH, Hadjiconstantinov M. Cyclic AMP-mediated enhancement of high-affinity choline transport and acetylcholine synthesis in brain. *J Neurochem* 68:1062–1070, 1997.
105. Ford BD, Ivy MT, Mtshali CP, Townsel JG. The involvement of protein kinase C in the regulation of choline cotransport in *Limulus*. *Comp Biochem Physiol A Mol Integr Physiol* 123:255–261, 1999.
106. Guyenet P, Lefresne P, Rossier J, Beaujouan JC, Glowinski J. Inhibition by hemicholinium-3 of (14C)acetylcholine synthesis and (3H)choline high-affinity uptake in rat striatal synaptosomes. *Mol Pharmacol* 9:630–639, 1973.
107. Lowenstein PR, Coyle JT. Rapid regulation of [3H] hemicholinium-3 binding sites in the rat brain. *Brain Res* 381:191–194, 1986.
108. Cooke LJ, Rylett RJ. Inhibitors of serine/threonine phosphatases increase membrane bound choline acetyltransferase activity and enhance acetylcholine synthesis. *Brain Res* 751:232–238, 1997.
109. Torres GE, Gainetdinov RR, Caron MG. Plasma membrane monoamine transporters: structure, regulation and function. *Nat Rev Neurosci* 4:13–25, 2003.
110. Diaz-Meco MT, Municio MM, Frutos S, Sanchez P, Lozano J, Sanz L, Moscat J. The product of par-4, a gene induced during apoptosis, interacts selectively with the atypical isoforms of protein kinase C. *Cell* 86:777–786, 1996.
111. Sells SF, Han SS, Muthukkumar S, Maddiwar N, Johnstone R, Boghaert E, Gills D, Liu G, Nair P, Monnig S, Collini P, Mattson MP, Sukhatme VP, Zimmer SG, Wood DV Jr., McRoberts JW, Shi Y, Rangnekar VM. Expression and function of the leucine zipper protein par-4 in apoptosis. *Mol Cell Biol* 17:3823–3832, 1997.
112. Guo Q, Fu W, Xie J, Luo H, Sells SF, Geddes JW, Bondada V, Rangnekar VM, Mattson MP. Par-4 is a mediator of neuronal degeneration associated with the pathogenesis of Alzheimer disease. *Nat Med* 4:957–962, 1994.

113. Chan SL, Tammariello SP, Estus S, Mattson MP. Prostate apoptosis response-4 mediates trophic factor withdrawal-induced apoptosis of hippocampal neurons: actions prior to mitochondrial dysfunction and caspase activation. *J Neurochem* 73:502–512, 1999.
114. Mattson MP, Duan W, Chan SL, Camandola S. Par-4: an emerging pivotal player in neuronal apoptosis and neurodegenerative disorders. *J Mol Neurosci* 13:17–30, 1999.
115. Guo Q, Sebastian L, Sopher BL, Miller MW, Glazner GW, Ware CB, Martin GM, Mattson MP. Neurotrophic factors [activity-dependent neurotrophic factor (ADNF) and basic fibroblast growth factor (bFGF)] interrupt excitotoxic neurodegenerative cascades promoted by a PS1 mutation. *Proc Natl Acad Sci U S A* 96:4125–4130, 1999.
116. Guo Q, Xie J, Chang X, Du H. Prostate apoptosis response-4 enhances secretion of amyloid β peptide 1–42 in human neuroblastomas IMR-32 cells by a caspase-dependent pathway. *J Biol Chem* 276:16040–16044, 2001.
117. Ferguson SM, Bazalakova M, Savchenko V, Tapia JC, Wright J, Blakely RD. Lethal impairment of cholinergic neurotransmission in hemicholinium-3-sensitive choline transporter knockout mice. *Proc Natl Acad Sci U S A* 101:8762–8767, 2004.
118. Jonker JW, Wagenaar E, Mol CAAM, Buitelaar M, Koepsell H, Smit JW, Schinkel AH. Reduced hepatic uptake and intestinal excretion of organic cations in mice with a targeted disruption of organic cation transporter 1 (Oct1[Slc 22a1]) gene. *Mol Cell Biol* 21:5471–5477, 2001.
119. Grundemann D, Gorboulev V, Gambaryan S, Vehyl M, Koepsell H. Drug excretion mediated by a new prototype of polyspecific transporter. *Nature* 372:549–552, 1994.
120. Gorboulev V, Ulzheimer JC, Akhoundova A, Ulzheimer-Teuber I, Karbach U, Quester S, Baumann C, Lang F, Busch AE, Koepsell H. Cloning and characterization of two human polyspecific organic cation transporters. *DNA Cell Biol* 16:871–881, 1997.
121. Schweife N, Barlow DP. The Lx1 gene maps to mouse chromosome 17 and codes for a protein that is homologous to glucose and polyspecific transmembrane transporters. *Mamm Genome* 7:735–740, 1996.
122. Okuda M, Saito H, Urakami Y, Takano M, Inui K. cDNA cloning and functional expression of a novel rat kidney organic cation transporter, OCT2. *Biochem Biophys Res Commun* 224:500–507, 1996.
123. Wu X, Kekuda R, Huang W, Fei YJ, Leibach FH, Chen J, Conway SJ, Ganapathy V. Identity of the organic cation transporter OCT3 as the extraneuronal monoamine transporter (uptake2) and evidence for the expression of the transporter in the brain. *J Biol Chem* 273:32776–32786, 1998.
124. Kakehi M, Koyabu N, Nakamura T, Uchiumi T, Kuwano M, Ohtani H, Sawada Y. Functional characterization of mouse cation transporter mOCT2 compared with mOCT1. *Biochem Biophys Res Commun* 296:644–650, 2002.
125. Gründemann D, Babin-Ebell J, Martel F, Örding N, Schmidt A, Schömig E. Primary structure and functional expression of the apical organic cation transporter from kidney epithelial LLC-PK₁ Cells. *J Biol Chem* 272:10408–10413, 1997.
126. Terashita S, Dresser MJ, Zhang L, Gray AT, Yost SC, Giacomini KM. Molecular cloning and functional expression of a rabbit renal organic cation transporter. *Biochim Biophys Acta* 1369:1–6, 1998.
127. Tamai I, Yabuuchi H, Nezu J, Sai Y, Oku A, Shimane M, Tsuji A. Cloning and characterization of a novel human pH-dependent organic cation transporter, OCTN1. *FEBS Lett* 419:107–111, 1997.
128. Wu X, Prasad PD, Leibach FH, Ganapathy V. cDNA sequence, transport function, and genomic organization of human OCTn2, a new member of the organic cation transporter family. *Biochem Biophys Res Commun* 246:589–595, 1998.
129. Meyer-Wentrup F, Karbach U, Gorboulev V, Arndt P, Koepsell H. Membrane localization of the electrogenic cation transporter rOCT1 in rat liver. *Biochem Biophys Res Commun* 248:673–678, 1998.
130. Karbach U, Kricke J, Meyer-Wentrup F, Gorboulev V, Volk C, Löffing-Cueni D, Kaissling B, Bachmann S, Koepsell H. Localization of organic cation transporters OCT1 and OCT2 in rat kidney. *Am J Physiol Renal Physiol* 279:F679–F687, 2000.
131. Grundemann D, Koster S, Kiefer N, Breidert T, Engelhardt M, Spitzenberger F, Obermüller N, Schömig E. Transport of monoamine transmitters by the organic cation transporter type 2, OCT2. *J Biol Chem* 273:30915–30920, 1998.
132. Kekuda R, Prasad PD, Wu X, Wang H, Fei Y, Leibach FH, Ganapathy V. Cloning and functional characterization of a potential-sensitive, polyspecific organic cation transporter (OCT3) most abundantly expressed in placenta. *J Biol Chem* 273:15971–15979, 1998.
133. Koepsell H, Gorboulev V, Arndt P. Molecular pharmacology of organic cation transporters in kidney. *J Membr Biol* 167:103–117, 1999.
134. Grundemann D, Liebich G, Kiefer N, Koster S, Schömig E. Selective substrates for non-neuronal monoamine transporters. *Mol Pharmacol* 56:1–10, 1999.
135. Sweet DH, Miller DS, Pritchard JB. Ventricular choline transport, a role for organic cation transporter 2 expressed in choroids plexus. *J Biol Chem* 276:41611–41619, 2001.
136. Zhang L, Schaner ME, Giacomini KM. Functional characterization of an organic cation transporter (hOCT1) in a transiently transfected human cell line (HeLa). *J Pharmacol Exp Ther* 286:354–361, 1998.
137. Martel F, Vetter T, Russ H, Grundemann D, Azevedo I, Koepsell H, Schömig E. Transport of small organic cations in the rat liver. The role of the organic cation transporter OCT1. *Naunyn Schmiedeberg Arch Pharmacol* 354:320–326, 1996.
138. Grundemann D, Schechinger B, Rappold GA, Schömig E. Molecular identification of the corticosterone-sensitive extraneuronal catecholamine transporter. *Nature Neurosci* 1:349–351, 1998.
139. Busch AE, Quester S, Ulzheimer JC, Waldegger S, Gorboulev V, Arndt P, Lang F, Koepsell H. Electrogenic properties and substrate specificity of the polyspecific rat cation transporter rOCT1. *J Biol Chem* 271:32599–32604, 1996.
140. Koehler MR, Wissinger B, Gorboulev V, Koepsell H, Schmid M. The two human organic cation transporter genes SLC22A1 and SLC22A2 are located on chromosome 6q26. *Cytogenet Cell Genet* 79:198–200, 1997.
141. Koehler MR, Gorboulev V, Koepsell HM, Steinlein C, Schmid M. Roct1, a rat polyspecific transporter gene for the excretion of cationic drugs, maps to chromosome 1q11–12. *Mamm Genome* 7:247–248, 1995.
142. Gorboulev V, Volk C, Arndt P, Akhoundova A, Koepsell H. Selectivity of the polyspecific cation transporter rOCT1 is changed by mutation of aspartate 475 to glutamate. *Mol Pharmacol* 56:1254–1261, 1999.
143. Volk C, Gorboulev V, Budiman T, Nagel G, Koepsell H. Different affinities of inhibitors to the outwardly and inwardly directed substrate binding site of organic cation transporter 2. *Mol Pharmacol* 64:1037–1047, 2003.
144. Jonker JW, Wagenaar E, Van Eijl S, Schinkel AH. Deficiency in the organic cation transporters 1 and 2 (Oct1/Oct2 [Slc22a1/Slc22a2]) in mice abolishes renal secretion of organic cations. *Mol Cell Biol* 23:7902–7908, 2003.
145. Jonker JW, Schinkel AH. Pharmacological and physiological functions of the polyspecific organic cation transporters: OCT1, 2, and 3 (SLC22A1–3). *J Pharmacol Exp Ther* 308:2–9, 2004.
146. Wu X, Gorge RL, Huang W, Wang H, Conway SJ, Leibach FH, Ganapathy V. Structural and functional characteristics and tissue distribution pattern of rat OCTN1, an organic cation transporter, cloned from placenta. *Biochim Biophys Acta* 1466:315–327, 2000.
147. Wu X, Huang W, Prasad PD, Seth P, Rajan DP, Leibach FH, Chen J, Conway SJ, Ganapathy V. functional characteristics and tissue

- distribution pattern of organic cation transporter 2 (OCTN2), an organic cation/carnitine transporter. *J Pharmacol Exp Ther* 290:1482–1492, 1999.
148. Traiffort E, Ruat M, O'Regan S and Meunier FM. Molecular characterization of the family of choline transporter-like proteins and their variants. *J Neurochem* 92:1116–1125, 2005.
149. O'Regan S, Traiffort E, Ruat M, Cha N, Compaoré D, Meunier F. An electric lobe suppressor for a yeast choline transport mutation belongs to a new family of transporter-like proteins. *Proc Natl Acad Sci U S A* 97:1835–1840, 2000.
150. Wille S, Szekeres A, Majdic O, Prager E, Staffler G, Stöckl J, Kunthalert D, Prieschl EE, Baumrucker T, Burtscher H, Zlabinger GJ, Knapp W, Stockinger H. Characterization of CDw92 as a member of the choline transporter-like protein family regulated specifically on dendritic cells. *J Immunol* 167:5795–5804, 2001.
151. Yuan Z, Wagner L, Poloumienko A, Bakovic M. Identification and expression of a mouse muscle-specific CTL1 gene. *Gene* 341:305–312, 2004.
152. Meunier FM, O'Regan S. Expression of CTL1 in myelinating structures of *Torpedo marmorata*. *Neuroreport* 13:1617–1620, 2002.
153. Yuan Z, Tie A, Tarnopolski M, Bakovic M. Genomic structure, expression and alternative splicing of the human choline transporter like protein. *Physiol Genomics* (in press), 2005.
154. Inazu M, Takeda H, Matsumiya T. Molecular and functional characterization of an Na⁺-independent choline transporter in rat astrocytes. *J Neurochem* 94:1427–1437, 2005.
155. Bishop WR, Bell RM. Assembly of phospholipids into cellular membranes: biosynthesis, transmembrane movement and intracellular translocation. *Annu Rev Cell Biol* 4:579–610, 1988.
156. O'Regan S, Meunier FM. Selection and characterization of the choline transport mutation suppressor from *Torpedo* electric lobe, CTL1. *Neurochem Res* 28:551–555, 2003.
157. Zufferey R, Santiago TC, Brachet V, Mamoun CB. Reexamining the role of choline transporter-like (Ct1p) proteins in choline transport. *Neurochem Res* 29:461–467, 2004.
158. Fullerton MD, Wagner L, Yuan Z, Bakovic M. Impaired trafficking of choline transporter like protein-1 at the plasma membrane and inhibition of choline transport in THP-1 monocyte-derived macrophages. *Am J Physiol Cell Physiol* 290:C1230–C1238, 2006.
159. Fujita T, Shimada A, Okada N, Yamamoto A. Functional characterization of Na(+)-independent choline transport in primary cultures of neurons from mouse cerebral cortex. *Neurosci Lett* 393:216–221, 2006.
160. Novakova J, Mikasova L, Machova E, Lisa V, Dolezal V. Chronic treatment with amyloid beta(1–42) inhibits non-cholinergic high-affinity choline transport in NG108–15 cells through protein kinase C signaling. *Brain Res* 1062:101–110, 2005.
161. Lecomte MJ, De Gois S, Guerci A, Ravassard P, Faucon Biguet N, Mallet J, Berrard S. Differential expression and regulation of the high-affinity choline transporter CHT1 and choline acetyltransferase in neurons of superior cervical ganglia. *Mol Cell Neurosci* 28:303–313, 2005.
162. Vissing K, Andersen JL, Harridge SD, Sandri C, Hartkopp A, Kjaer M, Schjerling P. Gene expression of myogenic factors and phenotype-specific markers in electrically stimulated muscle of paraplegics. *J Appl Physiol* 99:164–172, 2005.
163. Mouly V, Aamiri A, Bigot A, Cooper RN, Di Donna S, Furling D, Gidaro T, Jacquemin V, Mamchaoui K, Negroni E, Perie S, Renault V, Silva-Barbosa SD, Butler-Browne GS. The mitotic clock in skeletal muscle regeneration, disease and cell mediated gene therapy. *Acta Physiol Scand* 184:3–15, 2005.
164. Frenette J, Chbinou N, Godbout C, Marsolais D, Frenette PS. Macrophages, not neutrophils, infiltrate skeletal muscle in mice deficient in P/E selectins after mechanical reloading. *Am J Physiol Regul Integr Comp Physiol* 285:R727–R732, 2003.